We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-3.14%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.73B
AUM Growth
-$549M
Cap. Flow
-$263M
Cap. Flow %
-15.18%
Top 10 Hldgs %
58.51%
Holding
67
New
10
Increased
11
Reduced
11
Closed
18

Top Buys

Rank Stock Value
1
RAPP
Rapport Therapeutics
RAPP
+$68.1M
2
AXSM icon
Axsome Therapeutics
AXSM
+$29.6M
3
ALMS
Alumis Inc
ALMS
+$28.6M
4
PCVX icon
Vaxcyte
PCVX
+$28.2M
5
CGEM icon
Cullinan Oncology
CGEM
+$24M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$107M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$55.1M
3
AUTL
Autolus Therapeutics
AUTL
+$42.2M
4
BBIO icon
BridgeBio Pharma
BBIO
+$36.8M
5
ALXO icon
ALX Oncology
ALXO
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
51
DELISTED
Apellis Pharmaceuticals
APLS
– –
-400,000
Closed -$23.5M
ATXS
52
DELISTED
Astria Therapeutics
ATXS
– –
-1,300,000
Closed -$18.3M
AUTL
53
Autolus Therapeutics
AUTL
$532M
– –
-6,616,667
Closed -$42.2M
JBIO
54
Jade Biosciences
JBIO
$1.35B
– –
-30,566
Closed -$31.6M
BCAB icon
55
BioAtla
BCAB
$5.53M
– –
-23,417
Closed -$4.03M
BEAM icon
56
PUT
Beam Therapeutics
BEAM
$2.81B
– –
-300,000
Closed -$9.91M
CABA icon
57
Cabaletta Bio
CABA
$450M
– –
-1,100,000
Closed -$18.8M
IMRX icon
58
Immuneering
IMRX
$289M
– –
-3,295,273
Closed -$9.52M
IRON icon
59
Disc Medicine
IRON
$2.97B
– –
-125,000
Closed -$7.78M
NKTX icon
60
Nkarta
NKTX
$164M
– –
-1,350,000
Closed -$14.6M
RCKT icon
61
Rocket Pharmaceuticals
RCKT
$387M
– –
-300,000
Closed -$8.08M
SYRE icon
62
Spyre Therapeutics
SYRE
$9.12B
– –
-250,000
Closed -$9.48M
TRML
63
DELISTED
Tourmaline Bio
TRML
– –
-1,250,000
Closed -$28.6M
VTYX
64
DELISTED
Ventyx Biosciences
VTYX
– –
-2,710,000
Closed -$14.9M
KYTX icon
65
Kyverna Therapeutics
KYTX
$471M
– –
-440,000
Closed -$10.9M
ALPN
66
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-2,700,000
Closed -$107M
MRNS
67
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-3,250,000
Closed -$29.4M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Cormorant Asset Management held 67 positions worth $1.73B, down 24% from $2.28B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management withdrew a net $263M in Q2 2024, closing 18 positions and reducing 11 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Rapport Therapeutics worth $68.4M.

  • Cormorant Asset Management's largest Q2 2024 buy was Rapport Therapeutics: 2,940,283 shares worth $68.4M.
  • Cormorant Asset Management added most to Vaxcyte in Q2 2024, an estimated $28.2M increase.
  • Cormorant Asset Management's biggest Q2 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $55.1M.
  • Cormorant Asset Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $107M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.73B portfolio in Q2 2024.
  • Cormorant Asset Management opened 10 new positions and closed 18 in Q2 2024.
  • Cormorant Asset Management's portfolio value fell 24% quarter-over-quarter to $1.73B.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.